Volvo Autonomous Solutions’ rollout of its transport-as-a-service offering ramped up a couple of notches in recent days.

An investigator presented 90-day safety results from the first human trial of a proprietary water-soluble hydrogel injected into the vas deferens for non-permanent contraception.